摘要
Abstract
Objective:To investigate the efficacy of Sintilimab combined with Taxol+Platinum(TP)chemotherapy regimen in the treatment of advanced non small cell lung cancer(NSCLC)patients and its effects on tumor markers and immune balance.Method:A total of 88 patients with advanced NSCLC admitted to Shouguang People's Hospital from January 2022 to September 2023 were selected and divided into control group(TP chemotherapy)and observation group(TP chemotherapy combined with Sintilimab)according to random number table method,with 44 cases in each group.The remission efficiency,tumor markers,immune indexes and adverse reactions were compared between two groups.Result:The total remission rate of the observation group was 84.09%,which was higher than 59.09%of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant difference in carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA),CD3+,CD4+and CD8+(P>0.05).After treatment,CA125,CA153,CEA and CD8+in observation group were lower than those in control group,while CD3+and CD4+were higher than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between two groups(P>0.05).Conclusion:TP chemotherapy combined with Sintilimab has a significant remission effect in the treatment of advanced NSCLC,which can further down-regulate the expression of tumor markers and regulate immune balance,with high safety.关键词
晚期非小细胞肺癌/信迪利单抗/TP化疗/肿瘤标志物/免疫Key words
Advanced non small cell lung cancer/Sintilimab/TP chemotherapy/Tumor markers/Immune
